EGFR and neoplasm: Among them, 11C-erlotinib and 18F-afatinib showcased the most promising tumor-to-background contrast in EGFR-positive lesions, while 11C-osimertinib exhibited the highest SUV and tumor-to-background ratio AUC values across various tissues [21].